By

Luke Timmerman

11
Dec
2017

Biotech’s Test: Root for a Tax Windfall Or Support the Next Generation of Scientists?

Grad students are underpaid and underappreciated. Many barely scrape by. Stagnant grant funding for science and uncertain career prospects are the norm. Yet we all know grad students are the mitochrondria of the scientific enterprise. Without them, PIs wouldn’t be looking like geniuses in Nature and Science. Biotech companies wouldn’t have enough of the worker bees they need. Now we...
Read More
29
Nov
2017

The Long Run Podcast: Steve Holtzman on Becoming a Biotech Political Activist

Steve Holtzman is the latest guest on The Long Run podcast. He’s the president and CEO of Boston-based Decibel Therapeutics, a venture-backed startup developing treatments for hearing loss. Holtzman has been a familiar figure around biotech for more than 30 years. He has had leadership roles at Millennium Pharmaceuticals, Infinity Pharmaceuticals, and Biogen. Little known fact: He was a founder...
Read More
26
Oct
2017

VIDEO: Climbing Mount Everest to Support Cancer Research at Fred Hutch

Hi, I’m Luke Timmerman, a biotech journalist. I’m carrying my 80-pound training backpack, up and down the hills of Seattle, for a reason. I’m training to climb Mt. Everest, the highest mountain in the world, in 2018. Why do this? Of course, I love the mountains. But mostly, I’m doing it to support the top-notch research at the Fred Hutchinson...
Read More
25
Oct
2017

Richard Pops on Fighting the Opioid Painkiller Crisis

Today’s guest on “The Long Run” podcast is Richard Pops. He’s the chairman and CEO of Alkermes. He is one of the seniormost executives in the biopharma industry, having joined Alkermes as CEO back in 1991. The company is known for its technology around making long-lasting injectable drugs, especially for mass-market chronic diseases like schizophrenia and diabetes. I’ve known Pops...
Read More
1 2 3 17